USAID Approves MedMira’s CE Marked Reveal HIV Test - 500 Beiträge pro Seite
eröffnet am 04.04.12 15:40:14 von
neuester Beitrag 22.05.12 07:07:33 von
neuester Beitrag 22.05.12 07:07:33 von
Beiträge: 13
ID: 1.173.475
ID: 1.173.475
Aufrufe heute: 0
Gesamt: 677
Gesamt: 677
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 19.06.11, 13:50 | 159 | |
| gestern 12:46 | 109 | |
| 02.07.09, 11:22 | 87 | |
| gestern 21:35 | 82 | |
| 24.01.14, 16:47 | 69 | |
| vor 1 Stunde | 67 | |
| gestern 23:06 | 54 | |
| 21.02.13, 13:43 | 42 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.749,00 | -0,14 | 172 | |||
| 2. | 2. | 149,93 | -3,55 | 121 | |||
| 3. | 3. | 7,0000 | -5,41 | 78 | |||
| 4. | 7. | 6,7290 | +2,08 | 58 | |||
| 5. | 6. | 6,6100 | +7,48 | 57 | |||
| 6. | 4. | 2.375,89 | -0,11 | 55 | |||
| 7. | 5. | 0,1845 | -8,21 | 54 | |||
| 8. | 8. | 3,7400 | +3,82 | 51 |
Feedback
Hallo, liebe Biotech-Gemeinde...
Hier Dürfte sich heute einiges verdienen lassen...
Die zugehörige News von heute
Halifax, Nova Scotia, April 4, 2012 – MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, announced today that the Company’s most advanced rapid HIV test, Reveal HIV, has been approved by the United States Agency for International Development (USAID) for inclusion on its list of approved rapid HIV tests.
Since its inception in 1986, the USAID HIV/AIDS program has invested over $7 billion to fight this global crisis. USAID is a key partner in the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the largest and most diverse HIV/AIDS prevention, care, and treatment initiative in the world.
With this approval and listing, MedMira’s CE-marked rapid HIV tests, in addition to the previously listed FDA-approved rapid HIV test, are eligible for procurement with funds provided by USAID. This new approval further strengthens the Company’s global rapid HIV test product line and serves as a strong foundation for MedMira to bring forward its other rapid diagnostic product lines, including Multiplo, for similar programs and approvals.
“We are very pleased with this latest approval and MedMira will continue to expand upon its portfolio of products within organizations such as USAID and PEPFAR in order to meet the increasing global demand, particularly in developing countries, for high quality rapid diagnostics,” said Hermes Chan, CEO, MedMira Inc. “With the addition of three formats of MedMira’s CE-marked rapid HIV test, projects funded by USAID and PEPFAR will be able to select the right format of the product for their testing initiative and further global HIV prevention and control efforts.”
Organizations purchasing Reveal HIV from the approved USAID list can now select the format and packaging that best suits their program needs. The various Reveal HIV product configurations available through USAID offer customers choice, flexibility and convenience whether their testing program is taking place in a hospital setting, a voluntary testing clinic, or through a mobile testing vehicle.
Chan continued, “The Reveal HIV product line satisfies the needs of a broad range of USAID sponsored testing programs. Resource-constrained testing programs can use the convenient and cost-effective all-in-one package for fingerstick, point-of-care testing while reference laboratories and other clinical settngs can use the veni-puncture whole blood/serum/plasma formats for batch testing. The two laboratory formats offer customers significantly decreased administrative costs and testing time, a key advantage over other rapid HIV testing technology in large scale, government screening programs.”
Und der Tages-Chart:
Hier Dürfte sich heute einiges verdienen lassen...
Die zugehörige News von heute
Halifax, Nova Scotia, April 4, 2012 – MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, announced today that the Company’s most advanced rapid HIV test, Reveal HIV, has been approved by the United States Agency for International Development (USAID) for inclusion on its list of approved rapid HIV tests.
Since its inception in 1986, the USAID HIV/AIDS program has invested over $7 billion to fight this global crisis. USAID is a key partner in the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the largest and most diverse HIV/AIDS prevention, care, and treatment initiative in the world.
With this approval and listing, MedMira’s CE-marked rapid HIV tests, in addition to the previously listed FDA-approved rapid HIV test, are eligible for procurement with funds provided by USAID. This new approval further strengthens the Company’s global rapid HIV test product line and serves as a strong foundation for MedMira to bring forward its other rapid diagnostic product lines, including Multiplo, for similar programs and approvals.
“We are very pleased with this latest approval and MedMira will continue to expand upon its portfolio of products within organizations such as USAID and PEPFAR in order to meet the increasing global demand, particularly in developing countries, for high quality rapid diagnostics,” said Hermes Chan, CEO, MedMira Inc. “With the addition of three formats of MedMira’s CE-marked rapid HIV test, projects funded by USAID and PEPFAR will be able to select the right format of the product for their testing initiative and further global HIV prevention and control efforts.”
Organizations purchasing Reveal HIV from the approved USAID list can now select the format and packaging that best suits their program needs. The various Reveal HIV product configurations available through USAID offer customers choice, flexibility and convenience whether their testing program is taking place in a hospital setting, a voluntary testing clinic, or through a mobile testing vehicle.
Chan continued, “The Reveal HIV product line satisfies the needs of a broad range of USAID sponsored testing programs. Resource-constrained testing programs can use the convenient and cost-effective all-in-one package for fingerstick, point-of-care testing while reference laboratories and other clinical settngs can use the veni-puncture whole blood/serum/plasma formats for batch testing. The two laboratory formats offer customers significantly decreased administrative costs and testing time, a key advantage over other rapid HIV testing technology in large scale, government screening programs.”
Und der Tages-Chart:
Anbei noch die Homepage und die vorletzte News zu den Geschäftszahlen:
medmira.com/
MedMira Reports Second Quarter Results
Halifax, Nova Scotia, March 30, 2012 – MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three and six month periods ending January 31, 2012.
"MedMira is beginning to see sales growth in Latin America & the Caribbean region as well as continuing market expansion in Asia Pacific, in particular China,” said Hermes Chan, CEO, MedMira Inc. “These regions, and others, are developing with the help of the Company’s strategic partners who are focusing on the public health programs and government tender opportunities. While the private sector and various niche markets, such as defence, remain as lucrative opportunities for MedMira in developed regions of the world, the public health sector is maturing and the demand for advanced, high quality diagnostics with a track record of performance is increasing.”
Second Quarter Financial Highlights
The Company recorded revenue from product sales of $274,188 as compared to $188,793 for the same quarter last year.
The revenue increase was primarily attributable to the Company’s sales growth in Asia Pacific and Latin America & the Caribbean. The Company recorded revenue from Asia Pacific and Latin America product sales of $89,296 as compared to $1,822 for the same period last year.
Gross profit for the quarter was $210,956 compared to $87,812 in the same period in 2011.
Total operating expenses decreased to $684,569 in the quarter ended January 31, 2012, compared to $710,842 during the same period in 2011. The decrease in operating expenses is attributed to the reimbursement of R&D expenses associated with the US Army contract.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company’s tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira’s rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events including statements regarding possible future growth and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
MedMira Contact:
Andrea Young, Corporate Communications
Tel: 902-450-1588
Email: ayoung@medmira.com
medmira.com/
MedMira Reports Second Quarter Results
Halifax, Nova Scotia, March 30, 2012 – MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three and six month periods ending January 31, 2012.
"MedMira is beginning to see sales growth in Latin America & the Caribbean region as well as continuing market expansion in Asia Pacific, in particular China,” said Hermes Chan, CEO, MedMira Inc. “These regions, and others, are developing with the help of the Company’s strategic partners who are focusing on the public health programs and government tender opportunities. While the private sector and various niche markets, such as defence, remain as lucrative opportunities for MedMira in developed regions of the world, the public health sector is maturing and the demand for advanced, high quality diagnostics with a track record of performance is increasing.”
Second Quarter Financial Highlights
The Company recorded revenue from product sales of $274,188 as compared to $188,793 for the same quarter last year.
The revenue increase was primarily attributable to the Company’s sales growth in Asia Pacific and Latin America & the Caribbean. The Company recorded revenue from Asia Pacific and Latin America product sales of $89,296 as compared to $1,822 for the same period last year.
Gross profit for the quarter was $210,956 compared to $87,812 in the same period in 2011.
Total operating expenses decreased to $684,569 in the quarter ended January 31, 2012, compared to $710,842 during the same period in 2011. The decrease in operating expenses is attributed to the reimbursement of R&D expenses associated with the US Army contract.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company’s tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira’s rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events including statements regarding possible future growth and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
MedMira Contact:
Andrea Young, Corporate Communications
Tel: 902-450-1588
Email: ayoung@medmira.com
Antwort auf Beitrag Nr.: 43.001.663 von ghaq am 04.04.12 15:47:44tote hose.
Schon alles irgenwie komisch.
Lese mich auch gerade erst ein.
Das Komischste derzeit finde ich , dass am 28. November schon der Jahresabschluss publiziert wird.
Frage mich aber auch gerade warum es nicht weiter hoch geht zumal der Geschäftsjahresbericht für 2011 angibt , dass die Umsatzzahlen für 2011 in Nordamerika rückläufig sind bzw. waren ...
The revenue decrease was primarily attributable to the Company’s decreased sales in North America. The Company recorded revenue from North American product sales of $540,340 as compared to $876,478 for the same period last year.
Das dürfte wohl ab heute als ein Aurutscher in der Vergangenheit zu deuten sein.
Die News von heute sind jedenfalls super diesbezüglich.
Was ich allerdings noch nicht weiß ist, wie teuer so ein Hiv-Test von denen ist und was die Konkurenz auf dem Markt dazu so alles anbietet und zu welchem Preis...
Lese mich auch gerade erst ein.
Das Komischste derzeit finde ich , dass am 28. November schon der Jahresabschluss publiziert wird.
Frage mich aber auch gerade warum es nicht weiter hoch geht zumal der Geschäftsjahresbericht für 2011 angibt , dass die Umsatzzahlen für 2011 in Nordamerika rückläufig sind bzw. waren ...
The revenue decrease was primarily attributable to the Company’s decreased sales in North America. The Company recorded revenue from North American product sales of $540,340 as compared to $876,478 for the same period last year.
Das dürfte wohl ab heute als ein Aurutscher in der Vergangenheit zu deuten sein.
Die News von heute sind jedenfalls super diesbezüglich.
Was ich allerdings noch nicht weiß ist, wie teuer so ein Hiv-Test von denen ist und was die Konkurenz auf dem Markt dazu so alles anbietet und zu welchem Preis...
Okay, dass der Jahresabschluss im November veröffentlicht wurde liegt wohl daran, dass das Finanzjahr bei Medmira am 31. July endet...
Trading Spotlight
Scheinbar gibt es nur zwei Anbieter für solche Art (Enzyme-linked Immunosorbent Assay (ELISA)) von HIV-Tests...
Siehe http://www.medcompare.com/matrix/1665/HIV-Screening---ELISA.…
Na ja...
Orasure der andere Anbieter kommt mit einer Marktkapitalisierung von 414,70 Mio. Euro daher und Medmira mit einer derzeitigen MK von nur 3,4 Mio. Euro.
Muss natürlich jeder selber wissen wo er bei Hiv-Test-Anbietern investiert.
Siehe http://www.medcompare.com/matrix/1665/HIV-Screening---ELISA.…
Na ja...
Orasure der andere Anbieter kommt mit einer Marktkapitalisierung von 414,70 Mio. Euro daher und Medmira mit einer derzeitigen MK von nur 3,4 Mio. Euro.
Muss natürlich jeder selber wissen wo er bei Hiv-Test-Anbietern investiert.
Antwort auf Beitrag Nr.: 43.002.091 von ghaq am 04.04.12 16:40:38das juckt die holzfäller nicht.die zocken nicht so gern.bei den amis wären wir jetzt schon bei 0,10.
Antwort auf Beitrag Nr.: 43.002.091 von ghaq am 04.04.12 16:40:38insaiderkäufe im februar. 70 millionen gesammt.
Der Orasure-Test kostet für 1x testen 34,95 US-$.
Bin gespannt, wie viel der andere Test von Medmira wohl kostet.
Weiß es vielleicht schon jemand.
Bin gespannt, wie viel der andere Test von Medmira wohl kostet.
Weiß es vielleicht schon jemand.
Antwort auf Beitrag Nr.: 43.002.277 von ghaq am 04.04.12 17:04:40kein interresse das ding hochzuschießen.spreat in germanien viel zu hoch.wer kauft schon 100% über pari.
Antwort auf Beitrag Nr.: 43.002.374 von ultrawuffsn am 04.04.12 17:17:35pari wäre 0,036 euro.
Zur Zeit gibt es welche (186.047 Stk.) für 0,043 Euro in Frankfurt...
Und neue Nachrichten. Hmmm...
Und neue Nachrichten. Hmmm...
Pari wäre mitlerweile beim Kurs 0,04 $ , 0,031 Euro, wenn man bedenkt das der Euro zur Zeit bei 1,278 zum Us-Dollarkurs steht.
Mal sehen ich lege mir glaube ich noch welche zu...
Mal sehen ich lege mir glaube ich noch welche zu...
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 172 | ||
| 120 | ||
| 78 | ||
| 57 | ||
| 56 | ||
| 54 | ||
| 54 | ||
| 53 | ||
| 44 | ||
| 40 |
| Wertpapier | Beiträge | |
|---|---|---|
| 38 | ||
| 31 | ||
| 30 | ||
| 28 | ||
| 27 | ||
| 27 | ||
| 26 | ||
| 23 | ||
| 22 | ||
| 20 |
